-
13-09-2016, 10:26 PM
#141
Another one thats slipped through my widespread out fingers (sigh). Very int sector and subject. My father was, and possibly me , in the macular degeneration zone so its of personal interest. Has it 4 bagged for you DH?
-
14-09-2016, 09:45 PM
#142
Thanks for your response JT. Nice to think this company may help you and millions of others. Yes has 4 bagged for me Still has potential upside, and with test results lower downside risk.
-
14-09-2016, 10:32 PM
#143
Nice report here on Innate Immunotherapeutics (currently testing a treatment for MS), a spec buy with a relatively low risk thanks to a heap of positive non-trial results. Something like 80% of the current Phase IIb trial patients have requested ongoing treatment beyond the end of the trial which is a very positive indicator of the drug's efficacy. Results due next year. Have held this for a couple of years.
http://www.innateimmuno.com//irm/com...storsTakeToIIL
-
23-12-2016, 07:28 PM
#144
Its been a while folks. In fact i forgot about this thread. Only holding NRT atm as I'm in concrete with this.Will persevere a while ,until a hammer drill materializes ( i accept fault.So forgot all about OPT which has been a stellar performer along with these and 2017 top 6 picks(what a performance in 2016.
http://www.innateimmuno.com/irm/comp...opSixPicks2017
-
24-12-2016, 12:13 AM
#145
Member
should add CYP to the biotech list, surprised it's not listed in there
pretty hot little stem cell company, been rising steadily last few months
still low market cap, but has made great progress in 2016 and huge potential
dyor, etc
-
23-01-2017, 03:04 PM
#146
Biotech set to regain favour? Mainly covers the bigger biotech stocks - FPH gets a mention.
http://www.theage.com.au/business/bi...04-gtm71i.html
-
23-01-2017, 09:07 PM
#147
Interesting article thanks. Good to see both Wilsons and Bell Potter share my positive view on Opthea
-
24-03-2017, 10:58 AM
#148
Have bought BOT since my last post and have just seen they too are on the marijuana thing . Anything that mentions cannabis is multi bagging atm (see marijuana thread). Didn't buy BOT for a flakey; crazy, short lived dangerous trade like that but i guess its abonus if the s/p does get a boost. BOT have many other trials and things in progress so its not like a short one horse race. S/P hasn't gone ballistic since announcement below.Not a recco DYOR
Today Botanix Pharmaceuticals released a new company update presentation, available for viewing on the ASX here. The presentation outlines Botanix’s compelling investment case and strategy.
Investment Highlights:
• Experienced US based leadership team in place with a proven track record of achieving FDA approvals
• Addressing growing, multi-billion dollar dermatology markets with no new products approved in last 20 years (within the acne space)
• Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical development success
• Exclusive global rights to use PermetrexTM delivery technology for all drugs that treat skin diseases with potential to deliver near term revenues
• Accelerated development pathway for dermatology pharmaceuticals compared to standard development pathways, driving lower costs and a faster timeline to approval
• Strong intellectual property portfolio which includes 12 patent applications across 6 patent families, and substantial volumes of proprietary knowledge, know-how, and trade secrets
• Multiple near term potential revenue streams to complement longer term development upside
Matthew Callahan, Executive Director, commented, “Recent enhancements to Botanix’s senior leadership, expansion of the PermetrexTM license and new patent applications ensures Botanix is well positioned to capitalise on early value creation opportunities. Our focus now is on the rapid commercialisation of our lead acne product and developing our wider portfolio of medical dermatology products.”
Last edited by Joshuatree; 24-03-2017 at 12:26 PM.
-
05-04-2017, 12:34 PM
#149
-
05-04-2017, 02:27 PM
#150
BOT holding up extremely well atm with re 23% dilution ;cap raise to Instos at 5.5c.S/P has dropped only to 6.6c atm. Maybe I'm a bit early with my enthusiasm and those Instos will sell down; but so far a very strong endorsement of all the products BOT has.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks